A Study to Learn About the Effectiveness of the Medicine Called Elranatamab in People With Relapsed Refractory Multiple Myeloma as Compared With Standard of Care Therapies

CompletedOBSERVATIONAL

Enrollment

Participants

Timeline

Start Date

August 26, 2024

Primary Completion Date

March 3, 2025

Study Completion Date

March 3, 2025

Conditions

Multiple Myeloma

Interventions

DRUG

Elranatamab

BCMA-CD3 bispecific antibody

DRUG

Standard of care

Trial Locations (1)

Pfizer, New York